Physician profile
Christopher J Heller
NPI 1619263191
$2,626.44
in general payments reported to CMS, 2019-2025
26 companies · $32.58 in 2025
The $32.58 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $154 · 2021: $851 · 2022: $587 · 2023: $336 · 2024: $314 · 2025: $32.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.39 | 2021-2024 | |
| Novo Nordisk INC | $315.76 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $266.17 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $265.99 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.59 | 2020-2023 | Ofev |
| Genentech USA, INC. | $155.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $121.06 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $91.29 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $57.31 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $55.68 | 2019 | |
| Amgen INC. | $47.65 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.16 | 2021-2022 | |
| Dynavax Technologies Corporation | $43.65 | 2021-2022 | |
| Grifols USA, LLC | $41.14 | 2024 | Prolastin-C Liquid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $39.18 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $20.78 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $19.21 | 2023 | Korlym |
| Pfizer INC. | $18.55 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $16.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.17 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.54 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.25 | 2019 | |
| Ibsa Pharma INC. | $14.87 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.94 | 2022 | |
| Orexo US, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.